Logo image of ALNFL.PA

NFL BIOSCIENCES SA (ALNFL.PA) Stock Fundamental Analysis

Europe - Euronext Paris - EPA:ALNFL - FR0014003XT0 - Common Stock

1.12 EUR
+0.09 (+8.74%)
Last: 12/5/2025, 7:00:00 PM
Fundamental Rating

2

ALNFL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. The financial health of ALNFL is average, but there are quite some concerns on its profitability. ALNFL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ALNFL had negative earnings in the past year.
In the past 5 years ALNFL always reported negative net income.
In the past 5 years ALNFL always reported negative operating cash flow.
ALNFL.PA Yearly Net Income VS EBIT VS OCF VS FCFALNFL.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2023 2024 -1M -2M -3M -4M

1.2 Ratios

The Return On Assets of ALNFL (-50.64%) is worse than 66.27% of its industry peers.
ALNFL has a Return On Equity (-84.25%) which is in line with its industry peers.
Industry RankSector Rank
ROA -50.64%
ROE -84.25%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALNFL.PA Yearly ROA, ROE, ROICALNFL.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2023 2024 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ALNFL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALNFL.PA Yearly Profit, Operating, Gross MarginsALNFL.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ALNFL has been increased compared to 1 year ago.
The number of shares outstanding for ALNFL has been increased compared to 5 years ago.
Compared to 1 year ago, ALNFL has an improved debt to assets ratio.
ALNFL.PA Yearly Shares OutstandingALNFL.PA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2023 2024 2M 4M 6M 8M
ALNFL.PA Yearly Total Debt VS Total AssetsALNFL.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2023 2024 1M 2M 3M

2.2 Solvency

An Altman-Z score of 3.93 indicates that ALNFL is not in any danger for bankruptcy at the moment.
ALNFL's Altman-Z score of 3.93 is fine compared to the rest of the industry. ALNFL outperforms 77.11% of its industry peers.
ALNFL has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.01, ALNFL belongs to the top of the industry, outperforming 80.72% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 3.93
ROIC/WACCN/A
WACCN/A
ALNFL.PA Yearly LT Debt VS Equity VS FCFALNFL.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2023 2024 1M 2M 3M

2.3 Liquidity

A Current Ratio of 2.35 indicates that ALNFL has no problem at all paying its short term obligations.
ALNFL has a Current ratio (2.35) which is comparable to the rest of the industry.
ALNFL has a Quick Ratio of 2.35. This indicates that ALNFL is financially healthy and has no problem in meeting its short term obligations.
ALNFL's Quick ratio of 2.35 is in line compared to the rest of the industry. ALNFL outperforms 55.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.35
Quick Ratio 2.35
ALNFL.PA Yearly Current Assets VS Current LiabilitesALNFL.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2023 2024 1M 2M 3M

More info and screens

1

3. Growth

3.1 Past

ALNFL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.35%, which is quite impressive.
EPS 1Y (TTM)54.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-423.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 85.12% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-93.75%
EPS Next 2Y-81.43%
EPS Next 3Y85.12%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALNFL.PA Yearly Revenue VS EstimatesALNFL.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2027 5M 10M 15M
ALNFL.PA Yearly EPS VS EstimatesALNFL.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6 -0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ALNFL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALNFL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALNFL.PA Price Earnings VS Forward Price EarningsALNFL.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALNFL.PA Per share dataALNFL.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 -0.2 -0.3

4.3 Compensation for Growth

ALNFL's earnings are expected to grow with 85.12% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-81.43%
EPS Next 3Y85.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALNFL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NFL BIOSCIENCES SA

EPA:ALNFL (12/5/2025, 7:00:00 PM)

1.12

+0.09 (+8.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.08%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap14.19M
Revenue(TTM)N/A
Net Income(TTM)-1.83M
Analysts81.82
Price Target2.99 (166.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.11%
PT rev (3m)-35.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)11.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.54
P/tB 7.02
EV/EBITDA N/A
EPS(TTM)-0.36
EYN/A
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.17
TBVpS0.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.64%
ROE -84.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.35
Quick Ratio 2.35
Altman-Z 3.93
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-423.53%
EPS Next Y-93.75%
EPS Next 2Y-81.43%
EPS Next 3Y85.12%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y34.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-136.84%
EBIT Next 3Y94.59%
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

NFL BIOSCIENCES SA / ALNFL.PA FAQ

Can you provide the ChartMill fundamental rating for NFL BIOSCIENCES SA?

ChartMill assigns a fundamental rating of 2 / 10 to ALNFL.PA.


Can you provide the valuation status for NFL BIOSCIENCES SA?

ChartMill assigns a valuation rating of 1 / 10 to NFL BIOSCIENCES SA (ALNFL.PA). This can be considered as Overvalued.


What is the profitability of ALNFL stock?

NFL BIOSCIENCES SA (ALNFL.PA) has a profitability rating of 0 / 10.


What is the expected EPS growth for NFL BIOSCIENCES SA (ALNFL.PA) stock?

The Earnings per Share (EPS) of NFL BIOSCIENCES SA (ALNFL.PA) is expected to decline by -93.75% in the next year.